SUREFLAP LIMITED
Get an alert when SUREFLAP LIMITED files next
Leroy will email you the moment a new filing lands at Companies House — one short note per filing, nothing else.
Next accounts due
2026-09-30 (in 4mo)
Last filed for 2024-12-31
Confirmation statement due
2027-01-20 (in 8mo)
Last made up 2026-01-06
Watchouts
None on the register
Cash
—
Latest balance sheet
Net assets
-£2M
+93.8% vs 2023
Employees
86
-2.3% vs 2023
Profit before tax
-£17M
-36.7% vs 2023
Net assets
2-year trend · vs Basic Materials median
Accounts
2-year trend · latest reflected 2024-12-31
| Metric | Trend | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Turnover | £30,585,000 | £21,520,000 | |
| Operating profit | -£8,845,000 | -£13,500,000 | |
| Profit before tax | -£12,233,000 | -£16,725,000 | |
| Net profit | -£6,839,000 | -£16,429,000 | |
| Cash | £1,311,000 | — | |
| Total assets less current liabilities | -£26,894,000 | -£1,318,000 | |
| Net assets | -£27,260,000 | -£1,689,000 | |
| Equity | -£27,260,000 | -£1,689,000 | |
| Average employees | 88 | 86 | |
| Wages | £6,630,000 | £5,705,000 |
Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers
Ratios
Computed from the line items above — sparklines read oldest → newest
| Ratio | Trend | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating margin | -28.9% | -62.7% | |
| Net margin | -22.4% | -76.3% | |
| Return on capital employed | 32.9% | 1024.3% | |
| Current ratio | 0.59x | 0.92x | |
| Interest cover | -2.27x | -4.15x |
Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.
Audit & accounting basis
- Accounting basis
- FRS 102
- Reporting scope
- Standalone (parent only)
- Auditor
- PricewaterhouseCoopers LLP
- Audit opinion
- Unqualified (clean)
- Going concern
- Affirmed
“The Directors have prepared the financial statements on a going concern basis. Before confirming the appropriateness of the going concern basis of preparation, the Directors reviewed and considered the following: The latest cash flow forecasts going out beyond 12 months from the date of signing the financial statements. These are based on the Directors' collective view of likely trading conditions underpinned by a prudent assessment of the performance of the economies in which they will operate over that period including severe and plausible possible downside scenarios. The relative strength of the Group's balance sheet in this context. The level of cash held by the Group and Company and access to further third-party debt. As at 31 December 2024 the company had net liabilities of £1,689,000 (2023: liabilities £27,260,000). The Group will provide financial support to the Company such that the Company is able to operate as a going concern and to settle its liabilities as they fall due. This financial support will include: Not seeking the repayment of amounts advanced to the Company by the Parent and/or other members of the Parent group unless adequate alternative financing has been secured by the Company; and Advancing further amounts to the Company as required by the Company. On 22 December 2025 Sureflap Limited issued Intervet Holding BV with 1 share at a premium, as detailed in the post balance sheet events section below and Note 22. The company therefore continues to adopt the going concern basis in preparing its financial statements.”
Significant events
- “On 26 November 2024 Sureflap Limited issued Intervet Holding BV with 1 share for £1 plus a premium of £41,999,999.”
- “R&D expenditure in 2024 remained at a consistent level to 2023 totalling £5.4m inclusive of wages and salary costs. This expenditure enabled the delivery of 23 releases covering app updates, firmware improvements, hardware releases, and cloud-platform enhancements during 2024.”
- “In March 2025 the sales and commercial operations of Sureflap Limited underwent a restructuring initiative. The total separation costs paid in 2025 totalled £620,000.”
- “On 22 December 2025 Sureflap Limited issued Intervet Holding BV with 1 share at a nominal value of £1 with a premium of £6,499,999.”
- “Subsequent to the balance sheet date, the Company identified a significant decline in the net realizable value of certain inventory items due to changes in market conditions and also the planned launch of a new product. The Company expects that both products can coexist in the marketplace through the end of 2028. However, in light of these factors, an additional provision for inventory write-down amounting to £1.2 million has been made, reflecting the anticipated reduction in the recoverable value of the affected inventory.”
Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers
People
3 active · 13 resigned
| Name | Role | Appointed | Born | Nationality |
|---|---|---|---|---|
| GRUEN, Jeffrey | Director | 2022-02-11 | Feb 1980 | American |
| ROGERS, Martin Ian | Director | 2024-07-01 | Jun 1968 | British |
| ZIELINSKI-SMITH, Brian David | Director | 2025-07-30 | Feb 1983 | British |
Show 13 resigned officers
| Name | Role | Appointed | Resigned |
|---|---|---|---|
| GRUEN, Jeffrey | Secretary | 2022-02-11 | 2024-04-10 |
| HALLAS, David Charles | Secretary | 2019-12-23 | 2022-02-11 |
| HILL, Nicholas, Dr | Secretary | 2007-10-15 | 2019-12-23 |
| BANK, Andrew Douglas | Director | 2010-03-17 | 2025-04-30 |
| BOLTON, Brian Winston | Director | 2015-06-12 | 2020-12-16 |
| HALLAS, David Charles | Director | 2019-12-23 | 2022-02-11 |
| HESS, Hilton | Director | 2015-06-12 | 2019-12-23 |
| HILL, Jane, Dr | Director | 2007-10-15 | 2015-06-12 |
| HILL, Nicholas, Dr | Director | 2007-10-15 | 2019-12-23 |
| PARKER, Kevin David | Director | 2015-06-12 | 2019-12-23 |
| THORNE, Oliver George | Director | 2019-12-23 | 2022-02-11 |
| THROOP, Emily Dunn | Director | 2019-12-23 | 2022-02-11 |
| WILLIAMS, Amanda | Director | 2022-02-11 | 2024-07-01 |
Ownership
Persons with significant control
| Name | Kind | Nature of control | Notified | Status |
|---|---|---|---|---|
| Mr David Charles Hallas | Individual | Significant influence | 2019-12-23 | Ceased 2022-02-11 |
| Merck & Co., Inc. | Corporate entity | Shares 75–100%, Voting 75–100%, Appoints directors | 2019-04-01 | Active |
| Mr Brian Winston Bolton | Individual | Significant influence | 2016-04-06 | Ceased 2020-12-16 |
| Mr Hilton Hess | Individual | Significant influence | 2016-04-06 | Ceased 2019-12-23 |
| Dr Nicholas Hill | Individual | Significant influence | 2016-04-06 | Ceased 2019-12-23 |
| Mr Kevin David Parker | Individual | Significant influence | 2016-04-06 | Ceased 2019-12-23 |
| Mr Andrew Douglas Bank | Individual | Significant influence | 2016-04-06 | Ceased 2019-04-01 |
Filing timeline
Last 20 of 97 total filings
| Date | Type | Category | Description | |
|---|---|---|---|---|
| 2026-03-14 | AA | accounts | Accounts with accounts type full | |
| 2026-01-14 | CS01 | confirmation-statement | Confirmation statement with updates | |
| 2025-12-22 | SH01 | capital | Capital allotment shares | |
| 2025-08-19 | AP01 | officers | Appoint person director company with name date | |
| 2025-04-30 | TM01 | officers | Termination director company with name termination date | |
| 2025-04-02 | AA | accounts | Accounts with accounts type full | |
| 2025-01-07 | CS01 | confirmation-statement | Confirmation statement with updates | |
| 2024-11-27 | SH01 | capital | Capital allotment shares | |
| 2024-07-08 | AP01 | officers | Appoint person director company with name date | |
| 2024-07-03 | TM01 | officers | Termination director company with name termination date | |
| 2024-04-10 | TM02 | officers | Termination secretary company with name termination date | |
| 2024-03-29 | AA | accounts | Accounts with accounts type full | |
| 2024-03-28 | RP04CS01 | confirmation-statement | Second filing of confirmation statement with made up date | |
| 2024-03-20 | CS01 | confirmation-statement | Confirmation statement with updates | |
| 2024-03-18 | PSC07 | persons-with-significant-control | Cessation of a person with significant control | |
| 2024-03-18 | PSC02 | persons-with-significant-control | Notification of a person with significant control | |
| 2023-01-26 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2023-01-09 | AA | accounts | Accounts with accounts type full | |
| 2022-03-08 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2022-02-11 | AP03 | officers | Appoint person secretary company with name date |
Public-record activity
Raw counts from Companies House — last 12–24 months
- Filings
- 4
- Capital events
- 2
- Officers appointed
- 1
- Officers resigned
- 0
last 12 months
last 24 months
last 12 months
last 12 months
Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.
Year-on-year
FY2023 → FY2024 · period ending 2024-12-31 vs 2023-12-31
-
Turnover
-29.6%
£30,585,000 £21,520,000
-
Cash
—
Not reported
-
Net assets
+93.8%
-£27,260,000 -£1,689,000
-
Employees
-2.3%
88 86
-
Operating profit
-52.6%
-£8,845,000 -£13,500,000
-
Profit before tax
-36.7%
-£12,233,000 -£16,725,000
-
Wages
-14%
£6,630,000 £5,705,000
Each % is (latest − prior) ÷ |prior| for the line item as filed. The comparison is only shown when the latest and prior accounts cover broadly equal-length periods — short or long stubs (typical around incorporation or a year-end change) are suppressed rather than misrepresented. Lines a company doesn't report are omitted. About these numbers